A Staged Study Incorporating a Phase 1b, Multicenter, Unmasked, Dose Escalation Evaluation of Safety and Tolerability and a Phase 2, Multicenter, Unmasked, Randomized, Parallel Group, Controlled, Proof of Concept Investigation of Efficacy and Safety of ASP7317 for Atrophy Secondary to Age-related Macular Degeneration

Trial Profile

A Staged Study Incorporating a Phase 1b, Multicenter, Unmasked, Dose Escalation Evaluation of Safety and Tolerability and a Phase 2, Multicenter, Unmasked, Randomized, Parallel Group, Controlled, Proof of Concept Investigation of Efficacy and Safety of ASP7317 for Atrophy Secondary to Age-related Macular Degeneration

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs MA09 retinal pigment epithelial cell replacement therapy-Advanced Cell Technology (Primary) ; Mycophenolate mofetil; Tacrolimus
  • Indications Age-related macular degeneration
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Astellas Institute for Regenerative Medicine
  • Most Recent Events

    • 21 Sep 2017 Planned End Date changed from 28 Feb 2026 to 1 Oct 2026.
    • 21 Sep 2017 Planned primary completion date changed from 31 Aug 2020 to 1 Apr 2021.
    • 21 Sep 2017 Planned initiation date changed from 21 Aug 2017 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top